Glaukos (GKOS) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GKOS shares.
View GKOS analyst ratings or view top-rated stocks.

9 Wall Street analysts have issued 1 year target prices for Glaukos' shares. Their GKOS share price forecasts range from $48.00 to $90.00. On average, they predict the company's stock price to reach $79.00 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price.
View analysts price targets for GKOS or view top-rated stocks among Wall Street analysts.

Glaukos' stock was trading at $43.68 at the beginning of 2023. Since then, GKOS stock has increased by 63.4% and is now trading at $71.39.
View the best growth stocks for 2023 here.

Glaukos saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 6,480,000 shares, an increase of 9.6% from the August 15th total of 5,910,000 shares. Based on an average trading volume of 461,700 shares, the short-interest ratio is currently 14.0 days.
View Glaukos' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GKOS earnings forecast.

Glaukos Co. (NYSE:GKOS) posted its quarterly earnings data on Wednesday, August, 2nd. The medical instruments supplier reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.02. The medical instruments supplier had revenue of $80.40 million for the quarter, compared to analyst estimates of $74.73 million. Glaukos had a negative trailing twelve-month return on equity of 19.53% and a negative net margin of 42.61%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.83) earnings per share.

ETFs with the largest weight of Glaukos (NYSE:GKOS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Alger Weatherbie Enduring Growth ETF (AWEG), SPDR S&P Health Care Equipment ETF (XHE), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Corporate Culture Small Cap ETF (HAPS), Principal Healthcare Innovators ETF (BTEC), Xtrackers S&P SmallCap 600 ESG ETF (SMLE) and SPDR S&P SmallCap 600 ESG ETF (ESIX).

Glaukos updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $304.00 million-$308.00 million, compared to the consensus revenue estimate of $298.69 million.

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GKOS stock can currently be purchased for approximately $71.39.

Glaukos (NYSE:GKOS) has a market capitalization of $3.47 billion and generates $282.86 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

The company employs 783 workers across the globe.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.